You are here

FDA Reviewers Say Aclidinium Bromide Works, But Concerns About Heart Problems Remain

Food and Drug Administration staff said on Tuesday the drug, known generically as aclidinium bromide, reduced constriction of the lungs associated with chronic obstructive pulmonary disease (COPD).

Read the full article on Reuters.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs